Q-PCR Positive Control Plasmid for False Positive Differentiation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Biopharmaceutical manufacturing faces challenges in distinguishing between true positive and false positive results for biological contaminants due to cross-contamination in Q-PCR tests, leading to costly corrective actions.

Innovation Solution

A positive amplification control (PAC) plasmid with a unique artificial plasmid-specific sequence and a fluorescently labeled detection probe is used to differentiate between true positive and false positive signals in Q-PCR tests by incorporating a unique sequence that can be specifically identified, allowing for real-time differentiation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a positive amplification control is used in Q-PCR to ensure detection reliability, then the reliability of contaminant detection is improved, but false positive results increase due to cross-contamination

Engineering Contradiction:
Improvedetection reliabilityVSAvoidfalse positive results
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The positive amplification control plasmid is segmented into two distinct functional regions: a viral sequence region that amplifies with the contaminant-specific primers, and a unique artificial sequence region that amplifies only with the control-specific primers. This segmentation allows the control to simultaneously verify amplification functionality while providing a means to detect cross-contamination, thereby resolving the contradiction between reliability and false positives.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The unique artificial sequence acts as an intermediary marker that mediates between the positive control function and the false positive problem. By detecting this intermediary sequence separately from the viral sequence, the system can identify when cross-contamination has occurred, allowing differentiation between true positives and false positives caused by control contamination.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Productivity

If standard Q-PCR methodology is used to detect biological contaminants, then the measurement speed is improved, but the ability to distinguish true positives from false positives deteriorates

Engineering Contradiction:
Improvemeasurement speedVSAvoidpositive result accuracy
Core Design Contradiction:
ProductivityVSMeasurement precision

Solution Approach 1:

The detection system is segmented into two parallel amplification reactions: one targeting the viral sequence and another targeting the unique artificial sequence. This segmentation enables simultaneous execution of both detection tasks, maintaining the speed advantage of Q-PCR while adding the precision capability to distinguish true positives from false positives through comparative analysis of the two amplification results.

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables accurate identification of true positive Q-PCR signals by detecting the presence of the unique sequence, thereby reducing false positives and minimizing unnecessary corrective actions.

Implementation Method 1

a fluorescently labeled detection probe is used to differentiate between true positive and false positive signals in Q-PCR tests by incorporating a unique sequence that can be specifically identified

Methodology Applied
Scientific EffectFluorescent labeling: Fluorescence

Data Source

PatentUS20260015680A1Compositions and methods for detecting a biological contaminant
Publication Date: 2026.01.15 REGENERON PHARMACEUTICALS INC

AI summary

Provided are compositions and methods useful to the determination of whether a microbial contaminant is present in a biological therapeutic production process. Specifically, an artificial positive amplification control plasmid and unique quantitative PCR detection probe are provided, which enables the rapid and real-time detection of a false positive result.